Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUL-042 for Rhinovirus-induced Symptoms in Early COPD
NCT03794557Phase 2Completed
- Sponsor
- Pulmotect
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rhinovirus infection comparing PUL-042 with Placebo (2 arms). Primary endpoint: Lower Respiratory Symptom Score. Started Jan 2019; status: completed.
02
Drugs
PUL-042
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT03794557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794557.